IGC Pharma, Inc. (NYSE: IGC) a clinical-stage Biotechnology company developing treatments for Alzheimer’s Disease and Artificial Intelligence (AI) enabled healthcare technologies, today announced the beta release of its proprietary Agentic Harmonization Assistant (“AHA”), a patent-pending Healthcare AI platform designed to accelerate Alzheimer’s Drug Discovery, Clinical Research, Precision Medicine, and Pharmaceutical Development by helping researchers quickly combine and organize Alzheimer’s disease, aging-related, and other medical data that is often scattered across multiple databases, studies, hospitals, clinical trials, healthcare systems, and research institutions.
The announcement comes as IGC advances its lead Phase 2 Alzheimer’s Drug candidate, IGC-AD1, for agitation associated with Alzheimer’s Dementia, positioning the Company at the intersection of two rapidly expanding markets: Alzheimer’s Therapeutics and AI-Driven Healthcare Innovation.
Alongside IGC Pharma, Inc. (NYSE: IGC) watch Atlantic International Corp (NASDAQ: ATLN), Tianci Intl (NASDAQ: CIIT), Peraso Inc. (NASDAQ: PRSO) and Catheter Precision (NYSE: VTAK) all trading activity now.
“Artificial Intelligence, Machine Learning, and advanced Healthcare AI are transforming how new medicines are discovered and developed,” said Ram Mukunda, CEO of IGC Pharma. “Our vision is for AHA to become a foundational AI Infrastructure Platform that helps pharmaceutical companies, healthcare organizations, academic institutions, and government agencies transform fragmented Biomedical Data into interoperable, reusable, and AI-ready assets capable of supporting faster Drug Discovery, more efficient Clinical Trials, enhanced Precision Medicine, and accelerated Alzheimer’s Research.”
In internal testing using a representative Alzheimer’s Disease dataset containing 100 variables, AHA reduced estimated data harmonization time from approximately 28 hours to 2.5 hours, including human verification, representing an approximate 90% reduction in processing time. External beta testers have reported similar efficiency gains in comparable research environments.
IGC Pharma plans to demonstrate AHA in connection with the Alzheimer’s Disease Data Initiative’s AD Workbench ecosystem during the Alzheimer’s Association International Conference (AAIC) 2026 in London. The demonstration is expected to showcase AHA’s ability to support rapid cohort generation, cross-study analysis, collaborative research, Biomedical Data Harmonization, and AI-Powered Healthcare Analytics.
The Company believes Alzheimer’s Disease represents a high-value entry point into a much broader Healthcare Technology opportunity. IGC Pharma is expanding AHA’s architecture to support additional biomedical modalities, including Medical Imaging such as MRI, PET, and CT scans, as well as Genomics, Proteomics, and other Omics-Based Data.
With Alzheimer’s Disease affecting millions of people worldwide and investment accelerating across Artificial Intelligence, Healthcare AI, Precision Medicine, Machine Learning, Biotechnology, Drug Discovery, Clinical Research, and Neuroscience, IGC Pharma believes AHA positions the Company to participate in the growing convergence of AI-Powered Healthcare Innovation and Alzheimer’s Drug Development.
About IGC Pharma
IGC Pharma, Inc. (NYSE American: IGC) is a clinical-stage Biotechnology Company developing therapeutics for Alzheimer’s Disease and other indications. The Company’s lead asset, IGC-AD1, is currently being evaluated in the Phase 2 CALMA Clinical Trial for agitation associated with Alzheimer’s Dementia. The Company is also developing AI-Enabled Healthcare Technologies intended to support Biomedical Discovery, Drug Development, Clinical Research, Healthcare Analytics, and Precision Medicine initiatives.
About AHA
The Agentic Harmonization Assistant (AHA) is IGC Pharma’s proprietary AI-Enabled Platform designed to assist with the harmonization of complex Biomedical Datasets. AHA uses a patent-pending multi-agent, human-in-the-loop workflow to support dataset profiling, mapping, transformation, validation, and review across Healthcare, Pharmaceutical, and Clinical Research applications. AHA was originally developed to support MINT-AD, IGC Pharma’s predictive Alzheimer’s Risk Stratification engine. Training advanced Machine Learning, Artificial Intelligence, and Predictive Analytics models require large volumes of harmonized Biomedical Data; however, preparing those datasets manually remains one of the largest bottlenecks in Healthcare Research, Drug Development, Precision Medicine and Clinical Analytics. Alzheimer’s Research depends on large volumes of patient data collected across Clinical Trials, hospitals, research institutions, and healthcare systems. These datasets are frequently fragmented by inconsistent variable definitions, measurement units, study protocols, and clinical endpoints. Before modern AI Systems can generate reliable insights, the data must be harmonized to become clinically meaningful and interoperable across sources.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media ContactCompany Name: The Street ReportsContact Person: EditorEmail: Send EmailCountry: United StatesWebsite: http://www.thestreetreports.com
